Legal Opinion
Leo Pharmaceutical Products, Ltd. v. Rea
Court of Appeals for the Federal Circuit
Decided August 12, 2013No. 2012-1520PublishedCited by 63 opinions
1Opinion of the Court
RADER, Chief Judge.
This appeal arises from an inter partes reexamination of U.S. Patent No. 6,753,013 (the '013 patent). The '013 patent is owned by Leo Pharmaceutical Products, Ltd. (Leo Pharmaceuticals) and challenged by third party requester Galderma R & D. While the “substantial evidence” standard of review for fact findings made by the Board of Patent Appeals and Interferences (Board) 1 makes Leo Pharmaceutical’s burden on appeal a challenging one, after careful review, this court finds that Leo Pharmaceuticals has met that burden. Because the Board incorrectly construed the claim term…
2Cases cited16 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- Cybor Corporation v. Fas Technologies, Inc., and Fastar Ltd., Defendants-CrossCourt of Appeals for the Federal Circuit · 1998
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Stratoflex, Inc. v. Aeroquip CorporationCourt of Appeals for the Federal Circuit · 1983
- In Re Robert J. Gartside and Richard C. NortonCourt of Appeals for the Federal Circuit · 2000
11 more not listed; retrieve them via the Exa API.
3Cited by63 opinions
- Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.Court of Appeals for the Federal Circuit · 2014
- Broadcom Corporation v. Emulex CorporationCourt of Appeals for the Federal Circuit · 2013
- Nike, Inc. v. Adidas AgCourt of Appeals for the Federal Circuit · 2016
- Forest Laboratories, LLC v. Sigmapharm Laboratories, LLCCourt of Appeals for the Federal Circuit · 2019
- Acco Brands Corporation v. Fellowes, Inc.Court of Appeals for the Federal Circuit · 2016
58 more not listed; retrieve them via the Exa API.